Gri Bio Inc (GRI)

May 28, 2025

GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World

May 28, 2025

May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus

May 27, 2025

May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus

May 27, 2025

May 24, 2025

GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World

May 24, 2025

May 23, 2025

GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria

May 23, 2025

May 23, 2025

GRI Bio Expands Share Offering Agreement - TipRanks

May 23, 2025

May 23, 2025

GRI Bio expands at-the-market offering capacity - Investing.com

May 23, 2025

May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus

May 22, 2025

May 22, 2025

GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq

May 22, 2025

May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus

May 22, 2025

May 22, 2025

GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com

May 22, 2025

May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India

May 22, 2025

May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com

May 22, 2025

May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire

May 22, 2025

May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - Yahoo Finance

May 22, 2025

May 22, 2025

GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks

May 22, 2025

May 21, 2025

GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire

May 21, 2025

May 21, 2025

GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan

May 21, 2025

May 16, 2025

GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News

May 16, 2025

May 16, 2025

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times

May 16, 2025

May 16, 2025

GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan

May 16, 2025

May 15, 2025

GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India

May 15, 2025

May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus

May 15, 2025

May 15, 2025

GRI Bio reports positive early trial data for IPF treatment - Investing.com

May 15, 2025

May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus

May 15, 2025

May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times

May 15, 2025

May 15, 2025

GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq

May 15, 2025

May 15, 2025

GRI Bio, Inc. SEC 10-Q Report - TradingView

May 15, 2025

May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

May 15, 2025

May 09, 2025

GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria

May 09, 2025

May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire

May 08, 2025

May 08, 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com

May 08, 2025

May 08, 2025

GRI Bio reports positive interim biomarker data in IPF study - Investing.com

May 08, 2025

May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

May 08, 2025

May 07, 2025

GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com

May 07, 2025

May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire

May 07, 2025

May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times

May 07, 2025

May 02, 2025

GRI Bio (GRI) to Release Earnings on Friday - Defense World

May 02, 2025

Apr 24, 2025

GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 24, 2025

Apr 17, 2025

FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World

Apr 17, 2025

Apr 16, 2025

GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada

Apr 16, 2025

Apr 16, 2025

GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire

Apr 16, 2025

Apr 16, 2025

Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan

Apr 16, 2025

Apr 16, 2025

GRI Bio appoints Withum as new accounting firm - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright - Defense World

Apr 15, 2025

Apr 15, 2025

H.C. Wainwright maintains Buy on GRI Bio stock, $10 target - Investing.com Australia

Apr 15, 2025

Apr 14, 2025

H.C. Wainwright maintains Buy on GRI Bio stock, $10 target By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 09, 2025

GRI stock touches 52-week low at $1.2 amid market fluctuations - Investing.com

Apr 09, 2025